Skip to main content
Clinical Trials/NCT02215343
NCT02215343
Completed
Not Applicable

Effect of Prebiotic Fibre and Polyunsaturated Fatty Acid (PUFA) on the Gut Microbiota and Metabolic Risk Markers in a Metabolically Challenged Population

University of Copenhagen1 site in 1 country30 target enrollmentAugust 2014
ConditionsOverweight

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Overweight
Sponsor
University of Copenhagen
Enrollment
30
Locations
1
Primary Endpoint
Change in gut microbiota composition
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The main objective of this study is to investigate in detail how a high-(prebiotic)fibre diet and a high-PUFA diet affect the gut microbiota composition in a metabolic challenged population, and if the diet-induced modulation of the gut microbiota mediates changes in metabolic risk markers.

Intake of both experimental diets over 4 weeks are expected to induce beneficial changes in the gut microbiota composition and to affect markers for insulin sensitivity, lipid metabolism and inflammation. The investigators hypothesize that the effect of both interventions on the metabolic risk markers will be partly mediated by the diet-induced changes in the gut microbiota composition.

Registry
clinicaltrials.gov
Start Date
August 2014
End Date
June 2015
Last Updated
5 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Arne Astrup

Professor, Dr.Med.

University of Copenhagen

Eligibility Criteria

Inclusion Criteria

  • BMI: 25-40 kg/m2
  • Non-smoking
  • Indices of the Metabolic Syndrome defined by the International Diabetes Federation (IDF 2006):
  • Central obesity (waist circumference; men: ≥94 cm and women: ≥80 cm) + any one of the following; raised triglyceride level (≥1.7 mmol/L), reduced HDL cholesterol (men: \<1.03 mmol/L, women: \<1.29 mmol/L), raised BP (systolic ≥130 mm Hg or diastolic ≥85 mm Hg) or raised fasting plasma glucose (≥5.6 mmol/L).

Exclusion Criteria

  • Use of antibiotics
  • Weight change \>3 kg 2 months prior to study start
  • Intensive physical training/ elite athlete
  • Medication for dyslipidemia, type 2 diabetes or elevated blood pressure
  • Dietary supplements with pro/prebiotics, dietary fibre or fish oil supplement
  • Lactation, pregnancy or planning of pregnancy during the study
  • Gastro intestinal and liver disorders
  • Chronic inflammatory disorders
  • Diagnosed psychiatric disorder including treatment required depression
  • Surgical treatment of obesity and abdominal surgery

Outcomes

Primary Outcomes

Change in gut microbiota composition

Time Frame: Week 0, 4, 8, 12

Gut microbiota composition will be analyzed by use of fecal samples.

Secondary Outcomes

  • Faecal SCFA and bile acid composition(Week 0, 4, 8, 12)
  • Change in markers for lipid metabolism(Week 0, 4, 8, 12)
  • Change in markers for insulin sensitivity(Week 0, 4, 8, 12)
  • Change in markers for inflammation(Week 0, 4, 8, 12)
  • Lipidomics(Week 0, 4, 8, 12)
  • Metabolomics(Week 0, 4, 8, 12)

Study Sites (1)

Loading locations...

Similar Trials